Biological pathways provide evidence for how to overcome barriers limiting cancer immunotherapies

MD Anderson launches Institute for Cell Therapy Discovery & Innovation

The University of Texas MD Anderson Cancer Center launched its Institute for Cell Therapy Discovery & Innovation.

November 15, 2024

Combination immunotherapy + chemo is safe and effective for advanced small cell cancers in bladder and prostate

A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve treatment outcomes for patients with small cell bladder cancer and small cell/neuroendocrine prostate cancer.

November 15, 2024

Vol.50 No.43

Clinical Roundup

USC study identifies innate immune system protein as potential target for CRC immunotherapy

Researchers from the USC Norris Comprehensive Cancer Center found evidence that simultaneously targeting the innate and adaptive immune systems holds promise for treating aggressive colon cancer cases. The study has found evidence that targeting CD47, a protein that is part of the innate immune system, could be a key step in fighting colorectal cancer.

November 15, 2024

Vol.50 No.43

Regulatory News

FDA extends shelf-life for IV fluids in shortage after Hurricane Helene

More than a month has passed since Hurricane Helene took out Baxter North Cove plant, which manufactured 1.5 million IV fluid bags per day, supplying 60% of the intravenous solutions nationwide.

November 01, 2024

Vol.50 No.41

By Claire Marie Porter

In the aftermath of Helene and Milton, oncologists resort to airlifts to keep treatments on schedule
Helene knocks out Baxter facility, creating shortage of IV fluids

Hurricane Milton via satellite on Wednesday. Source: NOAA/NESDISSTAR GOES-EastMilton—the second hurricane in as many weeks—ripped through America’s southeast, causing severe flooding, washing away bridges, knocking out power and water supply.

October 11, 2024

Vol.50 No.38

By Claire Marie Porter

In Brief

Vanderbilt receives $1M grant to fund immunotherapy research in CRC

The Robert J. Kleberg Jr. and Helen C. Kleberg Foundation awarded a $1 million grant to support research at Vanderbilt aimed at dramatically expanding the efficacy of immunotherapy for colorectal cancer.

October 04, 2024

Vol.50 No.37

Biological pathways provide evidence for how to overcome barriers limiting cancer immunotherapies

YOU MAY BE INTERESTED IN

MD Anderson launches Institute for Cell Therapy Discovery & Innovation

Combination immunotherapy + chemo is safe and effective for advanced small cell cancers in bladder and prostate

USC study identifies innate immune system protein as potential target for CRC immunotherapy

FDA extends shelf-life for IV fluids in shortage after Hurricane Helene

In the aftermath of Helene and Milton, oncologists resort to airlifts to keep treatments on schedule
Helene knocks out Baxter facility, creating shortage of IV fluids

Vanderbilt receives $1M grant to fund immunotherapy research in CRC

Renew today!

Subscriber content

Never miss an issue!

Login

Biological pathways provide evidence for how to overcome barriers limiting cancer immunotherapies

YOU MAY BE INTERESTED IN

MD Anderson launches Institute for Cell Therapy Discovery & Innovation

Combination immunotherapy + chemo is safe and effective for advanced small cell cancers in bladder and prostate

USC study identifies innate immune system protein as potential target for CRC immunotherapy

FDA extends shelf-life for IV fluids in shortage after Hurricane Helene

In the aftermath of Helene and Milton, oncologists resort to airlifts to keep treatments on scheduleHelene knocks out Baxter facility, creating shortage of IV fluids

Vanderbilt receives $1M grant to fund immunotherapy research in CRC

Never miss an issue!

Login

In the aftermath of Helene and Milton, oncologists resort to airlifts to keep treatments on schedule
Helene knocks out Baxter facility, creating shortage of IV fluids